Short answer
Dyne Therapeutics, Inc. (DYN) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results covered quarter ended June 30, 2026.
Dyne Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Press release issued July 29, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for revenue, cash position, operating expenses, and pipeline updates
- Disclosure furnished under Regulation FD, limiting Section 18 Exchange Act liabilityેત્ર
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted z-rostudirsen’s DMD BLA with Priority Review; PDUFA action date January 21, 2027, supporting potential Q1 2027 launch
- ACHIEVE enrollment completed at 71 participants; topline z-basivarsen data planned Q1 2027, supporting potential accelerated-approval filing in Q3 2027
- July offering raised approximately $405.0 million net from 21,045,000 shares, extending expected cash runway into Q2 2028 but increasing dilution
- Cash, equivalents and marketable securities totaled $898.5 million at June 30, 2026; debt facility expanded to up to $400 million
- Quarterly net loss widened to $178.6 million from $110.9 million as R&D reached $152.2 million and launch preparation increased G&A to $29.5 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dyne Therapeutics, Inc. 8-K filings
Get the next DYN 8-K as it lands
Follow DYN for push alerts, or ask the research agent what this filing means.